{"disease":{"id":"geographic-atrophy-age-related-macular-degeneration","name":"geographic atrophy age related macular degeneration"},"drugs":{"marketed":[{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"avacincaptad","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avacincaptad","company_name":"Aviceda Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04770545","title":"An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":792,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02686658","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"IVERIC bio, Inc.","has_results":true},{"nct_id":"NCT05536297","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT07441642","title":"A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03845582","title":"Phase 2/3 Study of ALK-001 in Geographic Atrophy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Alkeus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01527500","title":"Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06961370","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06375239","title":"Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ray Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06662162","title":"Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"i-Lumen Scientific AUS PTY LTD","has_results":false},{"nct_id":"NCT07392255","title":"An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT07144137","title":"A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT06765980","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Kriya Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07214740","title":"Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06381596","title":"Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT06970665","title":"A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT07428798","title":"Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Marmara University Pendik Training and Research Hospital","has_results":false},{"nct_id":"NCT05391074","title":"Oral Postbiotics in Patients With Macular Atrophy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Institut de la Macula y la Retina","has_results":false},{"nct_id":"NCT03446144","title":"Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}